MNKD vs VTVT
MNKD: MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic and orphan lung diseases. VTVT: A late-stage biopharmaceutical company developing cadisegliatin, a liver-selective glucokinase activator in Phase 3 trials for type 1 diabetes, with FDA Breakthrough Therapy designation.
Side-by-side fundamentals
| Metric | MNKD | VTVT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.84 | $31.67 | |
| Market cap as of 2026-07-23 | $1.2B | $124M | |
| P/E as of 2026-07-23 | 212.36 | 55.08 | VTVT lower |
| Net margin as of 2026-07-23 | -6.4% | +65.5% | VTVT higher |
| Gross margin as of 2026-07-23 | +78.4% | n/a | |
| Operating margin as of 2026-07-23 | +4.1% | +63.1% | VTVT higher |
| ROE as of 2026-07-23 | -297.7% | +4.0% | VTVT higher |
| ROA as of 2026-07-23 | -3.8% | +2.9% | VTVT higher |
| Debt / equity as of 2026-07-23 | 9.95 | 0.00 | VTVT lower |
| Revenue growth (YoY) as of 2026-07-23 | +21.2% | +216600.0% | VTVT higher |
| Revenue CAGR (3y) SEC XBRL | +51.8% | n/a | |
| Beta as of 2026-07-23 | 1.12 | 0.29 | |
| 1-year return as of 2026-07-22 close | -2.3% | -69.6% | MNKD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.